- A case report of our second NSCLC patient treated by crizotinib2013 | Faculty of Medicine in Pilsen
- Crizotinib - Still "gold standard" for patients with pulmonary adenocarcinoma with ALK translocation?2017 | Faculty of Medicine in Pilsen
- Crizotinib as a next molecularly targeted drug in non small cell lung cancer2012 | Faculty of Medicine in Pilsen
- Successful Therapy of Czech Patients with ROS1 Translocation by Crizotinib2016 | Faculty of Medicine in Pilsen
- First experience on crizotinib therapy in non small cell lung cancer patient with EML-4 ALK translocation in Czech republic2012 | Faculty of Medicine in Pilsen
- Rare case of choroidal metastasis in ALK-positive NSCLC that responds to crizotinib2019 | First Faculty of Medicine
- First experiences with detecting ALK (anaplastic lymphoma kinase) gene rearrangement and administration of crizotinib in selected patients with non-small cell lung cancer (NSCLC)2012 | Faculty of Medicine in Pilsen
- Crizotinib - a multitargeted inhibitor as a molecularly targeted treatment in non small cell lung cancer2013 | Publication without faculty affiliation
- Crizotinib in the treatment of generalized non-small-cell lung cancer - a case report2017 | Publication without faculty affiliation
- Dlouhodobá léčebná odpověď na crizotinib u pacientky s adenokarcinomem plic2017 | First Faculty of Medicine
- Crizotinib - multitargeted inhibitor in targeted NSCLC therapyPublication without faculty affiliation
- ROS1 - another potencional target of our patients2014 | Faculty of Medicine in Pilsen
- Do metastases in the brain in a tumor with ALK translocation always mean ineffectiveness of crizotinib therapy?2017 | Faculty of Medicine in Pilsen
- Advanced lung cancer as chronic disease2015 | Faculty of Medicine in Pilsen
- Treatment of ALK positive non-small cell lung cancer2021 | First Faculty of Medicine
- Aggressive pulmonary adenocarcinoma with new FGFR translocation and cMET mutation not responsive to crizotinib and nintedanib treatment: a case report2020 | Faculty of Medicine in Pilsen
- Non-small cell lung cancer with ALK and R0S1 genes rearregement2018 | Faculty of Medicine in Pilsen
- Ceritinib - a new hope for patients with ALK-positive translocation of non-small-cell lung cancers2015 | Faculty of Medicine in Pilsen
- New treatment options - Non small cell lung cancer with rebuilding EML 4-ALK gene2014 | Faculty of Medicine in Pilsen
- Long time successful treatment of a young patient suffering from advanced ALK rearreged lung adenocarcinoma2018 | Faculty of Medicine in Pilsen, Second Faculty of Medicine
- A targeted diagnostic procedure and a treatment of an advanced lung carcinoma -the case report of a successful cooperation of four clinic departments, and crizotinib in a treatment of ROS 1 positive NSCLC2018 | Faculty of Medicine in Pilsen, First Faculty of Medicine
- Optimal procedure in treatments of advanced ALK-positive and ROS1-positive non-small cell lung cancers2019 | Third Faculty of Medicine
- Nemalobuněčný karcinom plic ROS1 pozitivní, léčený crizotinibem - kazuistika2018 | Second Faculty of Medicine
- Effects of Treatment with Crizotinib on Non-small Cell Lung Carcinoma with ALK Translocation in the Czech Republic2018 | Faculty of Medicine in Pilsen, First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Crizotinib - a novel multikinase inhibitor of signalling pathways for treatment in selected patients with non-small cell lung cancwer2013 | Faculty of Medicine in Pilsen
- Molecular pathology of pulmonary carcinomas2014 | Third Faculty of Medicine
- Molecular pathological predictive diagnostics in a patient with non-small cell lung cancer treated with crizotinib therapy: A case report2017 | First Faculty of Medicine, Second Faculty of Medicine
- Brigatinib2021 | First Faculty of Medicine
- The new moleculary targeted drug for the treatment of non small cell lung cancer (NSCLC)2011 | Faculty of Medicine in Pilsen
- Advances in NSCLC therapy - actual state of the art in biological targeted therapy2013 | Publication without faculty affiliation